223 related articles for article (PubMed ID: 33722977)
1. α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis.
Arakaki AKS; Pan WA; Wedegaertner H; Roca-Mercado I; Chinn L; Gujral TS; Trejo J
J Cell Sci; 2021 Apr; 134(8):. PubMed ID: 33722977
[TBL] [Abstract][Full Text] [Related]
2. The α-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling.
Arakaki AKS; Pan WA; Lin H; Trejo J
J Biol Chem; 2018 Mar; 293(9):3350-3362. PubMed ID: 29348172
[TBL] [Abstract][Full Text] [Related]
3. The α-Arrestin ARRDC3 Is an Emerging Multifunctional Adaptor Protein in Cancer.
Wedegaertner H; Pan WA; Gonzalez CC; Gonzalez DJ; Trejo J
Antioxid Redox Signal; 2022 May; 36(13-15):1066-1079. PubMed ID: 34465145
[No Abstract] [Full Text] [Related]
4. The α-arrestin ARRDC3 mediates ALIX ubiquitination and G protein-coupled receptor lysosomal sorting.
Dores MR; Lin H; J Grimsey N; Mendez F; Trejo J
Mol Biol Cell; 2015 Dec; 26(25):4660-73. PubMed ID: 26490116
[TBL] [Abstract][Full Text] [Related]
5. Divergent regulation of α-arrestin ARRDC3 function by ubiquitination.
Wedegaertner H; Bosompra O; Kufareva I; Trejo J
Mol Biol Cell; 2023 Aug; 34(9):ar93. PubMed ID: 37223976
[TBL] [Abstract][Full Text] [Related]
6. Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b.
Soung YH; Chung H; Yan C; Ju J; Chung J
Cells; 2019 Jul; 8(7):. PubMed ID: 31295851
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling.
Lin H; Trejo J
J Biol Chem; 2013 Apr; 288(16):11203-15. PubMed ID: 23476015
[TBL] [Abstract][Full Text] [Related]
8. Arrestin domain containing 3 promotes Helicobacter pylori-associated gastritis by regulating protease-activated receptor 1.
Liu YG; Teng YS; Shan ZG; Cheng P; Hao CJ; Lv YP; Mao FY; Yang SM; Chen W; Zhao YL; You N; Zou QM; Zhuang Y
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634127
[TBL] [Abstract][Full Text] [Related]
9. Termination of protease-activated receptor-1 signaling by beta-arrestins is independent of receptor phosphorylation.
Chen CH; Paing MM; Trejo J
J Biol Chem; 2004 Mar; 279(11):10020-31. PubMed ID: 14699102
[TBL] [Abstract][Full Text] [Related]
10. The α-Arrestin ARRDC3 Regulates the Endosomal Residence Time and Intracellular Signaling of the β2-Adrenergic Receptor.
Tian X; Irannejad R; Bowman SL; Du Y; Puthenveedu MA; von Zastrow M; Benovic JL
J Biol Chem; 2016 Jul; 291(28):14510-25. PubMed ID: 27226565
[TBL] [Abstract][Full Text] [Related]
11. ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.
Xiao J; Shi Q; Li W; Mu X; Peng J; Li M; Chen M; Huang H; Wang C; Gao K; Fan J
Am J Cancer Res; 2018; 8(1):132-143. PubMed ID: 29416926
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.
Soung YH; Kashyap T; Nguyen T; Yadav G; Chang H; Landesman Y; Chung J
Oncotarget; 2017 Aug; 8(32):52935-52947. PubMed ID: 28881784
[TBL] [Abstract][Full Text] [Related]
13. Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting Hippo pathway.
Wang Y; Liao R; Chen X; Ying X; Chen G; Li M; Dong C
Cell Death Dis; 2020 Jul; 11(7):520. PubMed ID: 32647142
[TBL] [Abstract][Full Text] [Related]
14. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.
Morris DR; Ding Y; Ricks TK; Gullapalli A; Wolfe BL; Trejo J
Cancer Res; 2006 Jan; 66(1):307-14. PubMed ID: 16397244
[TBL] [Abstract][Full Text] [Related]
15. ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP.
Shen X; Sun X; Sun B; Li T; Wu G; Li Y; Chen L; Liu Q; Cui M; Zhou Z
FEBS Lett; 2018 Feb; 592(4):599-609. PubMed ID: 29364502
[TBL] [Abstract][Full Text] [Related]
16. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Arora P; Cuevas BD; Russo A; Johnson GL; Trejo J
Oncogene; 2008 Jul; 27(32):4434-45. PubMed ID: 18372913
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds.
Soh UJ; Trejo J
Proc Natl Acad Sci U S A; 2011 Dec; 108(50):E1372-80. PubMed ID: 22106258
[TBL] [Abstract][Full Text] [Related]
18. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
19. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
20. Structural and biochemical basis for ubiquitin ligase recruitment by arrestin-related domain-containing protein-3 (ARRDC3).
Qi S; O'Hayre M; Gutkind JS; Hurley JH
J Biol Chem; 2014 Feb; 289(8):4743-52. PubMed ID: 24379409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
